ReviewMycobiology2024
A Comprehensive Review of the Diversity of Fungal Secondary Metabolites and Their Emerging Applications in Healthcare and Environment.
Review in Mycobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- What we (still don't) know about wood-degrading fungi: an overview of threats and utilization potentials.Applied microbiology and biotechnology · 2026Review
- Comparative Genomics Reveals Extensive Biosynthetic Diversity and Lineage-Specific Metabolic Potential AcrossJournal of fungi (Basel, Switzerland) · 2026Article
- Functional Characterization of Two Adjacent Oxygenase Genes,Journal of fungi (Basel, Switzerland) · 2026Article
- Ibotenic Acid and Muscimol inMolecules (Basel, Switzerland) · 2026Review
- Secondary Metabolite Biosynthesis and Regulatory Role of Sucrose inMicroorganisms · 2026Review
- Volatilomic Study of the Chemodiversity of Metabolites in Wild Macromycetes of the Lower Montane Humid Forest.Journal of fungi (Basel, Switzerland) · 2026Article
- Natural Photosensitizers in Cancer Therapy: A Chemo-Biodiversity Perspective on Light-Activated Natural Compounds.Chemistry & biodiversity · 2026Review
- Opportunistic pathogenicity in fungi can transcend species boundaries.bioRxiv : the preprint server for biology · 2026Article
- Phytochemical Profiling ofPlants (Basel, Switzerland) · 2026Article
- A report on the international conference on environmental mutagenesis in relation to human health held during the annual meeting of the Environmental Mutagen Society of India, January 29-31, 2026.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026Article
- Bacillus velezensis EU07 suppresses Fusarium graminearum via transcriptomic reprogramming.Applied microbiology and biotechnology · 2026Article
- Bee derived Aspergillus oryzae as a novel reservoir for selective anticancer metabolites with integrated bioprocess optimization and multi cell line evaluation.BMC microbiology · 2026Article
- Formulation Strategies for Fungal Biocontrol of Gastrointestinal Helminths in Domestic Animals and Plant-Parasitic Nematodes: A Review.Pathogens (Basel, Switzerland) · 2026Review
- Anti-staphylococcal activity of soil-derived Penicillium citrinum extract.BMC microbiology · 2026Article
- Sustainable production of insecticidal and acaricidal metabolites by endophytic fungi using solid-state fermentation.Scientific reports · 2026Article
- Extraction and characterization of a novel glycosylated naphthazarin pigment from mangrove Aspergillus unguis AUMC15225.Scientific reports · 2026Article
- Genetic Dereplication of MultipleJournal of natural products · 2026Article
- Article
- In vitro and in silico analysis of the fungicidal potential of secondary metabolites from a bacterial endophyte against Botrytis cinerea.BMC biotechnology · 2026Article
- New indole diketopiperazine from the fungus Penicillium chrysogenum.The Journal of antibiotics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungi and their natural products, like secondary metabolites, have gained a huge demand in the last decade due to their increasing applications in healthcare, environmental cleanup, and biotechnology-based industries. The fungi produce these secondary metabolites (SMs) during the different phases of their growth, which are categorized into terpenoids, alkaloids, polyketides, and non-ribosomal peptides. These SMs exhibit significant biological activity, which contributes to the formulation of novel pharmaceuticals, biopesticides, and environmental bioremediation agents. Nowadays, these fungal-derived SMs are widely used in food and beverages, for fermentation, preservatives, protein sources, and in dairy industries. In healthcare, it is being used as an antimicrobial, anticancer, anti-inflammatory, and immunosuppressive drug. The usage of modern tools of biotechnology can achieve an increase in demand for these SMs and large-scale production. The present review comprehensively analyses the diversity of fungal SMs along with their emerging applications in healthcare, agriculture, environmental sustainability, and nutraceuticals. Here, the authors have reviewed the recent advancements in genetic engineering, metabolic pathway manipulation, and synthetic biology to improve the production and yield of these SMs. Advancement in fermentation techniques, bioprocessing, and co-cultivation approaches for large-scale production of SMs. Investigators further highlighted the importance of omics technologies in understanding the regulation and biosynthesis of SMs, which offers an understanding of novel applications in drug discovery and sustainable agriculture. Finally, the authors have addressed the potential for genetic manipulation and biotechnological innovations for further exploitation of fungal SMs for commercial and environmental benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.